IG7.F MEMPHASYS LTD
- Market cap
- EUR 3.10M
- P/E
- -
- P/B
- 1.19x
- ROE
- -97.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is IG7.F undervalued?
Graham numberThe Graham number of MEMPHASYS LTD cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEMPHASYS LTD fundamental analysis
No fundamental analysis for MEMPHASYS LTD yet.
MEMPHASYS LTD stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In…
Full company profileMEMPHASYS LTD financial statements
MEMPHASYS LTD annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | - | 27.1K | 15.4K | 60.0K | 274K |
| Gross Profit | - | 8.24K | 9.22K | 1.61K | 305.00 |
| Operating Income | -1.96M | -2.73M | -3.63M | -5.24M | -4.15M |
| EBITDA | - | -1.51M | -2.47M | -3.41M | -3.13M |
| Net Income | -1.49M | -2.08M | -3.40M | -4.44M | -4.10M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||
| Total Assets | 13.7M | 14.1M | 14.7M | 12.4M | 11.2M |
| Total Liabilities | 5.97M | 6.47M | 7.28M | 5.59M | 7.02M |
| Shareholders' Equity | 8.61M | 7.65M | 7.38M | 6.84M | 4.21M |
| Cash & Short-term Investments | 2.00M | 269K | 638K | 278K | 1.18M |
| Cash Flow | |||||
| Capital Expenditure | 3.00M | 2.92M | 1.82M | 638K | 3.38K |
| Free Cash Flow | -2.96M | -2.61M | -3.23M | -3.87M | -2.49M |
| Ratios | |||||
| ROE | -17.3% | -27.2% | -46.1% | -65.0% | -97.4% |
| ROA | -10.8% | -14.7% | -23.2% | -35.7% | -36.5% |
| Net Profit Margin | - | -7,668.9% | -22,136.6% | -7,403.4% | -1,498.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEMPHASYS LTD dividends
MEMPHASYS LTD has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Nov 27, 2026.
Who owns MEMPHASYS LTD
- Insiders 38.86%
- Institutions 0.00%
- Public & others 61.14%
- Shares outstanding 3.10B
- Free float 1.61B
MEMPHASYS LTD company profile
- Company name
- MEMPHASYS LTD
- Ticker
- IG7.F
- ISIN
- AU000000MEM5
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 34-36 Richmond Road, Homebush, NSW, Australia, 2140
- Phone
- 61 2 8415 7300
- Website
- memphasys.com
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambient temperature semen transport device for artificial insemination in animals. In addition, the company develops ambient temperature storage product for human sperm; and a medium for human sperm isolation, fertilisation and cryopreservation. Memphasys Limited was incorporated in 2006 and is based in Homebush, Australia.
MEMPHASYS LTD management
3- Mr. David Raymond Tasker B.Com.Executive Chairman
- Prof. R. John Aitken Ph.D., ScD FRSEScientific Director
- Mr. Stefan RossCompany Secretary